GlassScriptPhysician profile
David S Schaub
NPI 1326261512
$1,538.93
in general payments reported to CMS, 2019-2025
11 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.98 · 2021: $169 · 2022: $347 · 2023: $358 · 2024: $260 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $620.30 | 2022-2025 | Infuse, Biotrue One Day, Xiidra |
| Alcon Vision LLC | $369.19 | 2021-2024 | Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $169.18 | 2019-2021 | |
| Biotissue Holdings INC. | $69.50 | 2022-2023 | |
| Lkc Technologies, INC. | $66.88 | 2023 | |
| Dompe US, INC. | $61.32 | 2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $58.66 | 2024 | Tecnis Iol |
| Harrow Eye, LLC | $39.37 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $35.79 | 2025 | Xdemvy |
| Abbvie INC. | $31.25 | 2025 | |
| Coopervision INC. | $17.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schaub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.